Donald Notman - 02 Jan 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Reporting relationship: Chief Financial Officer and Chief Operating Officer.
Issuer ticker: OCUL
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:01:55 UTC
Prior SEC filing: 04 Sep 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Todd Anderman, Attorney-in-Fact for Donald Notman

Key filing fact

Donald Notman filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 06 Jan 2026.

Key facts

This page summarizes Donald Notman's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 16:01.

Change

Previous filing in this sequence was filed on 04 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001718019 Primary reporting owner

Notman Donald

Relationship: Chief Financial Officer and Chief Operating Officer.
Address: C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD
Signature: /s/ Todd Anderman, Attorney-in-Fact for Donald Notman
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Award

Transaction value: $0
Shares: +79,112
Change %: +26%
Price: $0.000000
Shares after: 389,292
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +240,932
Change %
Price: $0.000000
Shares after: 240,932
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 240,932
Exercise price: $11.82
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

Footnote F2

Includes 1,373 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on December 31, 2025.

Footnote F3

Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

SEC remarks

Chief Financial Officer and Chief Operating Officer.